Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, Iomab-B that is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant. The company is also developing Actimab-A, its lead alpha-particle drug candidate that is in a Phase II trial for patients newly diagnosed with AML age 60 and over; and Actimab-M, a drug candidate, which is being studied in patients with relapsed or refractory multiple myeloma in a Phase 1 clinical trial. Its Antibody Warhead Enabling technology platform is currently being utilized in a research collaboration with Astellas Pharma, Inc. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone646-767-3870
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees30
Next Earnings Date11/8/2019 (Estimated)
OptionableOptionable
Actinium Pharmaceuticals (NASDAQ:ATNM) Frequently Asked Questions
What is Actinium Pharmaceuticals' stock symbol?
Actinium Pharmaceuticals trades on the NASDAQ under the ticker symbol "ATNM."
When is Actinium Pharmaceuticals' next earnings date?
What is the consensus analysts' recommendation for Actinium Pharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Actinium Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Actinium Pharmaceuticals.
Has Actinium Pharmaceuticals been receiving favorable news coverage?
News stories about ATNM stock have trended negative recently, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Actinium Pharmaceuticals earned a news sentiment score of -2.9 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for Actinium Pharmaceuticals.
Who are some of Actinium Pharmaceuticals' key competitors?
Some companies that are related to Actinium Pharmaceuticals include IMV (IMV), Cynata Therapeutics (CYP), BioTime (BTX), Ergomed (ERGO), Fennec Pharmaceuticals (FRX), Verseon (VSN), Burcon NutraScience (BU), Matinas BioPharma (MTNB), Matinas Biopharma (MTNB), Antibe Therapeutics (ATE), OncoCyte (OCX), Medlab Clinical (MDC), OncoCyte (OCX), Oxford Biodynamics (OBD) and Sirona Biochem (SBM).
Who are Actinium Pharmaceuticals' key executives?
Actinium Pharmaceuticals' management team includes the folowing people:
- Mr. Sandesh C. Seth, Chairman & CEO (Age 55)
- Mr. Steven O'Loughlin BS, Principal Financial & Accounting Officer (Age 33)
- Dr. Dale L. Ludwig Ph.D., Chief Scientific Officer (Age 57)
- Dr. Mark S. Berger, Chief Medical Officer (Age 64)
- Mr. Anil Kapur, Chief Commercial Officer (Age 50)
How do I buy shares of Actinium Pharmaceuticals?
Shares of ATNM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Actinium Pharmaceuticals' stock price today?
One share of ATNM stock can currently be purchased for approximately $0.22.
How big of a company is Actinium Pharmaceuticals?
What is Actinium Pharmaceuticals' official website?
How can I contact Actinium Pharmaceuticals?
The company can be reached via phone at 646-767-3870.
MarketBeat Community Rating for Actinium Pharmaceuticals (NASDAQ ATNM)
MarketBeat's community ratings are surveys of what our community members think about Actinium Pharmaceuticals and other stocks. Vote "Outperform" if you believe ATNM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATNM will underperform the S&P 500 over the long term. You may vote once every thirty days.
